摘要
目的观察中重度溃疡性结肠炎(UC)应用双歧杆菌三联活菌联合英夫利西单抗治疗的效果。方法选取2017年3月至2018年9月我院收治的92例UC患者,采用随机数字表法分为观察组和对照组各46例。对照组单用英夫利西单抗,观察组为双歧杆菌三联活菌与英夫利西单抗联合治疗。比较2组T细胞亚群、体液免疫指标[免疫球蛋白(Ig)G、IgA及IgM]。结果2组治疗后CD8^+下降,CD4^+、IgG、IgA均上升,且观察组变动幅度大于对照组,差异有统计学意义(P<0.05)。治疗后的CD8^+、CD4^+、IgG、IgA、IgM,与同组治疗前比较,差异有统计学意义(P<0.05)。结论针对中重度UC患者,应用双歧杆菌三联活菌与英夫利西单抗联合治疗可加快T细胞水平恢复正常,改善体液免疫。
Objective To observe the effects of bifid-triple viable combined with infliximab on immune function in patients with moderate-severe ulcerative colitis (UC).Methods Ninety-two patients with UC admitted in the hospital from March 2017 to September 2018 were selected,and they were divided into control group and observation group by random number table,with 46 cases in each group.Control group was given infliximab,while observation group was treated with bifid-triple viable and infliximab.The T lymphocyte subsets,humoral immunity indexes [immunoglobulin G (IgG),IgA,IgM] were compared between the two groups.Results After treatment,the CD8^+ in the two groups decreased,while the CD4^+,IgG and IgA in the two groups increased,and the changing range of observation group was larger than that in control group (P<0.05).There were significant difference between before and after treatment of same group in CD8^+,CD4^+,IgG,IgA and IgM(P<0.05).Conclusion Bifid-triple viable combined with infliximab in treatment of moderate-severe UC patients can accelerate recovery of T cell level,and improve humoral immunity.
作者
刘剑锋
Liu Jianfeng(Department of Digestive Medicine,the Second Hospital of Weinan City,Shaanxi 714000,China)
出处
《山西医药杂志》
CAS
2019年第11期1279-1281,共3页
Shanxi Medical Journal
